The big, the bad, and the exon 11: adjuvant imatinib for all gastro-intestinal stromal tumors or just the ugly?
作者信息
Groisberg Roman, Subbiah Vivek
机构信息
Department of Investigational Cancer Therapeutics (Phase 1 Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
出版信息
Transl Gastroenterol Hepatol. 2017 Oct 13;2:81. doi: 10.21037/tgh.2017.09.10. eCollection 2017.
Abstract
摘要
相似文献
1
The big, the bad, and the exon 11: adjuvant imatinib for all gastro-intestinal stromal tumors or just the ugly?大、恶与外显子11：辅助性伊马替尼是用于所有胃肠道间质瘤还是仅用于高危者？
Transl Gastroenterol Hepatol. 2017 Oct 13;2:81. doi: 10.21037/tgh.2017.09.10. eCollection 2017.
2
Subdural hematoma during therapy of gastro-intestinal stromal tumor (GIST) with Imatinib mesylate.在使用甲磺酸伊马替尼治疗胃肠道间质瘤（GIST）期间发生的硬膜下血肿。
Gulf J Oncolog. 2015 Jan;1(17):92-5.
3
Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas.辅助治疗伊马替尼后局部胃肠道间质瘤的一线酪氨酸激酶抑制剂治疗失败时间：欧洲癌症研究与治疗组织软组织和骨肿瘤协作组、澳大利亚胃肠肿瘤临床试验组、UNICANCER、法国肉瘤组、意大利肉瘤组和西班牙肉瘤研究组的一项随机临床试验。
J Clin Oncol. 2015 Dec 20;33(36):4276-83. doi: 10.1200/JCO.2015.62.4304. Epub 2015 Nov 16.
4
[Efficacy observation on imatinib reintroduction in gastrointestinal stromal tumor with high recurrence risk after imatinib adjuvant therapy failure].伊马替尼辅助治疗失败后高复发风险胃肠道间质瘤再次使用伊马替尼的疗效观察
Zhonghua Wei Chang Wai Ke Za Zhi. 2016 Nov 25;19(11):1286-1289.
5
Postoperative imatinib in patients with intermediate risk gastrointestinal stromal tumor.胃肠道间质瘤中危患者的术后伊马替尼治疗。
Future Oncol. 2018 Jul;14(17):1721-1729. doi: 10.2217/fon-2017-0691. Epub 2018 Jul 4.
6
[Analysis of imatinib trough concentration at steady state in adjuvant therapy of patients with high risk gastrointestinal stromal tumor].[高危胃肠道间质瘤患者辅助治疗中伊马替尼稳态谷浓度分析]
Zhonghua Wei Chang Wai Ke Za Zhi. 2019 Sep 25;22(9):848-855. doi: 10.3760/cma.j.issn.1671-0274.2019.09.009.
7
Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients.一项关于血小板衍生生长因子受体α（PDGFRA）第18外显子突变的胃肠道间质瘤患者的大型多中心观察性队列研究中的临床特征及治疗结果
Eur J Cancer. 2017 May;76:76-83. doi: 10.1016/j.ejca.2017.02.007. Epub 2017 Mar 8.
8
Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation.局部切除伴有 KIT 外显子 11 突变的高危 GIST 后，用甲磺酸伊马替尼进行 2 年辅助治疗。
Cancer Chemother Pharmacol. 2013 Jan;71(1):43-51. doi: 10.1007/s00280-012-1970-3. Epub 2012 Oct 7.
9
Mixed response on regorafenib treatment for GIST (gastro-intestinal stromal tumor) according to F-FDG-PET/CT.根据 F-FDG-PET/CT，瑞戈非尼治疗 GIST（胃肠道间质瘤）的反应不一。
BMC Cancer. 2018 Mar 5;18(1):253. doi: 10.1186/s12885-018-4154-7.
10
Laparoscopic resection of gastro-intestinal stromal tumour.腹腔镜下胃肠道间质瘤切除术
J Pak Med Assoc. 2015 Nov;65(11):1228-30.
引用本文的文献
1
Sequencing PEComas: Viewing Unicorns through the Molecular Looking Glass.PEComas的测序：透过分子窥镜看独角兽。
Oncology. 2021;99(1):62-64. doi: 10.1159/000510650. Epub 2020 Oct 13.
2
Challenging Standard-of-Care Paradigms in the Precision Oncology Era.精准肿瘤学时代对护理标准范式的挑战
Trends Cancer. 2018 Feb;4(2):101-109. doi: 10.1016/j.trecan.2017.12.004. Epub 2018 Jan 12.
本文引用的文献
1
Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.辅助伊马替尼治疗胃肠间质瘤患者中 KIT 和 PDGFRA 突变对生存的影响：一项随机临床试验的探索性分析。
JAMA Oncol. 2017 May 1;3(5):602-609. doi: 10.1001/jamaoncol.2016.5751.
2
BLU-285, DCC-2618 Show Activity against GIST.BLU-285 和 DCC-2618 对 GIST 具有活性。
Cancer Discov. 2017 Feb;7(2):121-122. doi: 10.1158/2159-8290.CD-NB2016-165. Epub 2017 Jan 11.
3
Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.辅助伊马替尼治疗高危胃肠道间质瘤：一项随机试验分析。
J Clin Oncol. 2016 Jan 20;34(3):244-50. doi: 10.1200/JCO.2015.62.9170. Epub 2015 Nov 2.
4
Biomarker based clinical trial design.基于生物标志物的临床试验设计。
Chin Clin Oncol. 2014 Sep;3(3):39. doi: 10.3978/j.issn.2304-3865.2014.02.03.
5
The genetic landscape of gastrointestinal stromal tumor lacking KIT and PDGFRA mutations.缺乏KIT和PDGFRA突变的胃肠道间质瘤的基因图谱
Endocrine. 2014 Nov;47(2):401-8. doi: 10.1007/s12020-014-0346-3. Epub 2014 Jul 16.
6
Gastrointestinal stromal tumors with KIT exon 9 mutations: Update on genotype-phenotype correlation and validation of a high-resolution melting assay for mutational testing.具有 KIT 外显子 9 突变的胃肠道间质瘤：基因型-表型相关性的最新研究和用于突变检测的高分辨率熔解曲线分析方法的验证。
Am J Surg Pathol. 2013 Nov;37(11):1648-59. doi: 10.1097/PAS.0b013e3182986b88.
7
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.慢性髓性白血病（CML）药物的价格反映了癌症药物的不可持续价格：从一大群 CML 专家的角度来看。
Blood. 2013 May 30;121(22):4439-42. doi: 10.1182/blood-2013-03-490003. Epub 2013 Apr 25.
8
KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs).胃肠道间质瘤（GISTs）中的KIT和PDGFRA突变
Semin Diagn Pathol. 2006 May;23(2):91-102. doi: 10.1053/j.semdp.2006.08.006.
9
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.无病生存期与总生存期作为辅助性结肠癌研究的主要终点：来自18项随机试验中20898例患者的个体患者数据。
J Clin Oncol. 2005 Dec 1;23(34):8664-70. doi: 10.1200/JCO.2005.01.6071. Epub 2005 Oct 31.
Zotero 插件